Clinical trials: Pseudoprogression
Glioma
The circTeloDIAG: Liquid Biopsy for Glioma Tumor
Gliomas represent the most frequent primary brain tumor, with 2,500 to 3,000 new cases per year in France. Their diagnosis, although highly complex, is essential for determining patient management.
- Trial name
- circTeloDIAG (NCT04931732)
- Testing
- ctDNA analysis
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Glioma, Brain Neoplasms
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery
Background: Differentiating true progression (TP) from pseudoprogression (PsP) after glioma surgery remains a major clinical challenge because conventional magnetic resonance imaging (MRI) often cannot reliably distinguish these…
- Trial name
- ASL-TDD (NCT07687277)
- Testing
- Multiparametric MRI (3D-ASL and TDD-MRI)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Lanzhou University Second Hospital
Glioma, Malignant
FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
The goal of this clinical trial is to evaluate the performance characteristics of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional…
- Trial name
- FET PET in HGG (NCT06172595)
- Testing
- FET PET
- Where
- 2 sites in Singapore
- Volunteers
- 22 people
- Sponsor
- Singapore General Hospital
Radiation Injury, Radiation Necrosis
Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*
Using a multi-echo gradient echo sequence to calculate R2* and quantitative susceptibility maps and well as susceptibility-weighted imaging post processing the investigators hypothesize that the investigators would be able to…
- Trial name
- NCT02212964
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Centre for Functional and Metabolic Mapping
High Grade Glioma
Permeability Map to Distinguish Progression From Pseudoprogression in High-Grade Glioma
The aim of the present study is to assess whether a new method of quantifying therapy-associated hemodynamic alterations based on DCE MR imaging may help to distinguish pseudoprogression from true progression in patients with…
- Trial name
- NCT01499823
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Seoul National University Hospital
Glioma, Neoplasms
Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques
Contrast-enhanced MRI is the most common way for evaluating neuroepithelial tumor grading and monitoring for tumor recurrence,but the ability to predict tumor behavior remains very limited.In this study, the investigators will…
- Trial name
- NCT02622620
- Volunteers
- 86 people
- Sponsor
- Tang-Du Hospital
Glioblastoma
Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.
The goal of this interventional study is the development and validation of imaging markers, MRI and PET, plasma biomarkers, and/or cell markers that could support clinicians and researchers in differentiating pseudoprogression…
- Trial name
- NCT06113705
- Testing
- 18F-GE-180 PET, Advanced MRI, Collection of hematopoietic stem cells
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma, Radionecrosis of Brain
FET-PET-Guided Management of Pseudoprogression in Glioblastoma
The goal of this diagnostic randomised clinical trial is to determine, in glioblastoma patients with diagnostic uncertainty between pseudoprogression and tumor progression on follow-up MRI after chemoradiation, the added value of…
- Trial name
- FET-POPPING (NCT06480721)
- Testing
- Clinical management based on the index MRI and an additional [¹⁸F] FET PET scan
- Where
- 8 sites in Netherlands
- Volunteers
- 144 people
- Sponsor
- Veerle Ruijters
Glioblastoma
Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression
Glioblastoma is the most aggressive kind of brain cancer and leads on average to 20 years of life lost, more than any other cancer.
- Trial name
- NCT04359745
- Where
- 15 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Brain Malignancies, Pseudoprogression
Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies
To learn if advanced imaging methods can tell apart true progression (the disease has actually gotten worse) from pseudoprogression (the disease appears to have gotten worse, but it actually has not).
- Trial name
- NCT06199479
- Testing
- MRI Scan, CT Scan, Biopsy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma
Evaluating Tumor Pseudoprogression With FLT-PET and MRI
A standard treatment for glioblastoma is a combination of radiation and the drug temozolomide. This combination sometimes causing swelling (inflammation) of the brain tissue.
- Trial name
- NCT01105988
- Testing
- Radiologic exams
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
Glioblastoma
Early Diagnosis of Pseudoprogression Using 11C-Methionine PET-MRI After Concomitant Radiochemotherapy Treatment for Glioblastoma.
Pseudoprogression is a phenomenon related to post-treatment rearrangements (including radiation necrosis). It appears early in the first year after treatment and accounts for 30 to 50% of patients followed with glioblastoma.
- Trial name
- TIGRE (NCT03739333)
- Testing
- 11C-Methionine PET-MRI
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Brain Cancer
Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas
This is a pilot study. The purpose of this study is to test if an imaging tracer, not approved by the FDA, called 11C-Choline (11C-CH) is useful for evaluating your type of cancer. This tracer is used to perform PET scans.
- Trial name
- NCT02849171
- Testing
- PET scan, C-Choline
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma (GBM)
Advanced Diffusion MRI to Differentiate Tumor Recurrence From Pseudoprogression in Patients With Glioblastoma and Brain Metastases
This pilot study investigates whether advanced diffusion-weighted MRI (ADW-MRI) can differentiate between true tumor progression (TP) and a pseudoprogression (PsP) in patients with glioblastoma (GBM) or brain metastases.
- Trial name
- AiD-GLIO (NCT05911230)
- Testing
- Advanced diffusion-weighted MRI (ADW-MRI)
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Glioblastoma
Discerning Pseudoprogression vs True Tumor Growth in GBMs
One-third of all primary brain tumors are astrocytomas, the most common type of glioma. Grade 4 astrocytomas, more commonly known as glioblastomas (GBMs), represent about 50% of all gliomas (annual incidence of over 3 per…
- Trial name
- NCT02905643
- Testing
- Study subjects
- Volunteers
- 1 people
- Sponsor
- Ascension Health
PET / CT, Lung Carcinoma
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
Currently, there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy. Most patients rely on follow-up observations to monitor the disease, which does not meet clinical needs.
- Conditions
- PET / CT, Lung Carcinoma, Immunotherapy
- Trial name
- NCT06608160
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
This pilot phase II trial study evaluates the usefulness of the ferumoxytol steady state magnetic resonance imaging (MRI) technique for response assessment after pembrolizumab and radiation therapy in non-small cell lung cancer…
- Trial name
- NCT03325166
- Testing
- Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Rectal Cancer
A Study on the Accurate Evaluation of Pseudoprogression of Rectal Cancer Immunotherapy Based on Multitemporal and Multiparameter MRI
This project aims to use multi-temporal, multi-parameter MRI features, blood biomarkers, and clinical indicators to accurately assess pseudoprogression following immunotherapy in rectal cancer.
- Trial name
- NCT07381322
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Peiyi Xie
Glioma Glioblastoma Multiforme
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Subjects with histologically proven glioblastoma (GBM) who are suspected to have progression and are candidates for a surgical resection according to standard of care may be eligible for this study.
- Trial name
- Axumin (NCT03990285)
- Testing
- Axumin, Intravenous Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ali Nabavizadeh
Brain Lesions, Brain Metastasis
FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
This is a single arm, single center study of 15 patients with brain lesions being treated at UNC Hospitals. Subjects will undergo one (1) FLT-PET-MRI scan before their scheduled surgical biopsy of their brain lesion(s).
- Conditions
- Brain Lesions, Brain Metastasis, Brain Metastases
- Trial name
- NCT02328300
- Testing
- FLT PET/MR
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center